文献速递青光眼

青光眼合并慢性肾脏病患者使用局部碳酸酐酶抑制剂的风险:一项全国性人群研究

Risks of Topical Carbonic Anhydrase Inhibitors in Glaucoma Patients With Chronic Kidney Disease: A Nationwide Population-Based Study.
PubMed 文献 · Am J Ophthalmol · 2023-05-05

该全国性人群队列研究利用台湾全民健康保险研究数据库2000年1月至2009年6月的数据,比较了既患原发性开角型青光眼又患晚期慢性肾脏病的局部碳酸酐酶抑制剂使用者与非使用者的结局。结果显示使用者长期透析发生率更高(发生率 1,216.85 vs 764.17/100患者年;校正风险比 1.17,95%CI 1.01-1.37),因代谢性酸中毒住院率也更高(发生率 21.54 vs 11.87/100患者年;校正风险比 1.89,95%CI 1.07-3.36)。作者认为局部碳酸酐酶抑制剂可能与长期透析和代谢性酸中毒风险升高相关,在晚期慢性肾脏病患者中应谨慎使用。

要点

  • 局部碳酸酐酶抑制剂使用者长期透析发生率高于非使用者(1,216.85 vs 764.17/100患者年;校正风险比 1.17,95%CI 1.01-1.37)。
  • 使用者因代谢性酸中毒住院率高于非使用者(21.54 vs 11.87/100患者年;校正风险比 1.89,95%CI 1.07-3.36)。
  • 作者认为局部碳酸酐酶抑制剂在晚期慢性肾脏病患者中应谨慎使用。

核心结论

  • 局部碳酸酐酶抑制剂可能与原发性开角型青光眼合并透析前晚期慢性肾脏病患者的长期透析和代谢性酸中毒风险升高相关。
  • 作者认为在晚期慢性肾脏病患者中应谨慎使用局部碳酸酐酶抑制剂。

研究设计与样本

  • 全国性人群队列研究,使用台湾全民健康保险研究数据库2000年1月至2009年6月的数据。
  • 纳入诊断为青光眼(ICD-9 代码 365)且正在使用青光眼眼药(包括按全民健康保险药品代码选择的碳酸酐酶抑制剂)的晚期慢性肾脏病患者。
  • 采用Kaplan-Meier法比较碳酸酐酶抑制剂使用者与非使用者之间死亡率、长期透析和代谢性酸中毒的累积发生率。
  • 主要结局包括死亡率、肾脏结局(进展至血液透析)和代谢性酸中毒。

主要发现

  • 碳酸酐酶抑制剂使用者长期透析发生率高于非使用者(1,216.85 vs 764.17/100患者年;校正风险比 1.17,95%CI 1.01-1.37)。
  • 碳酸酐酶抑制剂使用者因代谢性酸中毒住院率高于非使用者(21.54 vs 11.87/100患者年;校正风险比 1.89,95%CI 1.07-3.36)。

临床怎么用

  • 作者认为局部碳酸酐酶抑制剂在晚期慢性肾脏病患者中应谨慎使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the risks of metabolic acidosis and renal outcomes after topical carbonic anhydrase inhibitor (CAI) use in patients with both primary open-angle glaucoma (POAG) and advanced chronic kidney disease (CKD). DESIGN: Nationwide, population-based cohort study. METHODS: This study was conducted with population data from Taiwan's National Health Insurance (NHI) Research Database between January 2000 and June 2009. Patients with advanced CKD who were diagnosed with glaucoma (International Classification of Diseases, Ninth Revision [ICD-9] code 365) and had been receiving eye drops for glaucoma (including carbonic anhydrase inhibitors selected by NHI drug code) were enrolled. Using Kaplan-Meier methods, we compared the cumulative incidence of mortality, long-term dialysis, and cumulative incidence of metabolic acidosis over time between CAI users and CAI non-users. Primary outcomes comprised mortality, renal outcome (progression to hemodialysis), and metabolic acidosis. RESULTS: In this cohort, topical CAI users had a higher incidence of long-term dialysis than non-users (incidence = 1,216.85 vs 764.17 events per 100 patient-years; adjusted hazard ratio = 1.17, 95% CI = 1.01-1.37). Hospital admissions due to metabolic acidosis were higher in CAI users compared with non-users (incidence = 21.54 vs 11.87 events per 100 patient-years; adjusted hazard ratio = 1.89, 95% CI = 1.07-3.36). CONCLUSIONS: Topical CAIs may be associated with higher risks of long-term dialysis and metabolic acidosis in patients with POAG and pre-dialysis advanced CKD. Therefore, topical CAIs should be used with caution in advanced CKD patients.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wang YC, Ling XC, Tsai WH, et al. Risks of Topical Carbonic Anhydrase Inhibitors in Glaucoma Patients With Chronic Kidney Disease: A Nationwide Population-Based Study. Am J Ophthalmol. 2023. PMID: 37149244. doi:10.1016/j.ajo.2023.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。